Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein

Journal of Clinical Investigation

Volumn 104, Issue 11, 1999, Pages 1583-1591

  Ohh, Michael ^a   Takagi, Yuichiro ^b   Aso, Teijiro ^b   Stebbins, Charles E ^c   Pavletich, Nikola P ^d   Zbar, Bert ^e   Conaway, Ronald C ^b   Conaway, Joan Weliky ^f   Kaelin Jr , William G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c Weill Cornell Medical Center   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PEPTIDE; TUMOR PROTEIN;

ARTICLE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; VON HIPPEL LINDAU DISEASE;

EID: 0033404668     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8161     Document Type: Article

References (32)

1. Ohh, M., and Kaelin, W.G., Jr. 1999. The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol. Med. Today. 5:257-263.
2. Crossey, P.A., et al. 1994. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenorype. Hum. Mol. Genet. 3:1303-1308.
3. Gnarra, J.R., et al. 1994. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7:85-90.
4. Eng, C., et al. 1995. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J. Med. Genet. 32:934-937.
5. Hofstra, R.M.W., et al. 1996. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J. Clin. Endocrinol. Metab. 81:2881-2884.
6. Kinzler, K., and Vogelstein, B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-170.
7. Iliopoulos, O., Ohh, M., and Kaelin, W. 1998. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. USA. 95:11661-11666.
8. Schoenfeld, A., Davidowitz, E., and Burk, R. 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA. 95:8817-8822.
9. Maher, E., and Kaelin, W.G. 1997. von Hippel-Lindau Disease. Medicine (Baltimore). 76:381-391.
10. Lee, S., et al. 1996. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl. Acad. Sci. USA. 93:1770-1775.
11. Lee, S., et al. 1999. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19:1486-1497.
12. Lonergan, K.M., et al. 1998. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18:732-741.
13. Maxwell, P., et al. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:271-275.
14. Aso, T., Lane, W.S., Conaway, J.W., and Conaway, R.C. 1995. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science. 269:1439-1443.
15. Pause, A., et al. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA. 94:2156-2161.
16. Kibel, A., Iliopoulos, O., DeCaprio J.D., and Kaelin, W.G. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science. 269:1444-1446.
17. Kishida, T., Srackhouse, T.M., Chen, E., Lerman, M.I., and Zbar, B. 1995. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer. 55:4544-4548.
18. Zbar, B., et al. 1996. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8:348-357.
19. Stebbins, C., Kaelin,W., Jr., and Pavletich, N. 1999. Structure of the VHL-Elongin C-Elongin B complex: implications for von Hippel-Lindau tumor suppressor function. Science. 284:455-461.
20. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W.G. 1995. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-826.
21. Ohh, M., et al. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell. 1:959-968.
22. Takagi, Y., Conaway, R., and Conaway, J. 1996. Characterization of elongin C functional domain required for interaction with elongin B and activation of elongin A. J. Biol. Chem. 271:1-7.
23. Garrett, K., et al. 1995. Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog. Proc. Natl. Acad. Sci. USA. 92:7172-7176.
24. Kaelin, W.G., Pallas, D.C., DeCaprio, J.A., Kaye, F.J., and Livingston, D.M. 1991. Identification of cellular proteins that can interact specifically with the T/EIA-binding region of the retinoblastoma gene product. Cell. 64:521-532.
25. Duan, D.R., et al. 1995. Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science. 269:1402-1406.
26. Zbar, B., et al. 1996. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8:348-357.
27. Stolle, C., et al. 1998. Improved detection of germline mutarions in the von Hippel-Lindau disease rumor suppressor gene. Hum. Mutat. 12:417-423.
28. Brower, C., et al. 1999. The elongin B ubiquitin homology domain: identification of elongin B sequences important for interaction with elongin C. J. Biol. Chem 274:13629-13636.
29. Kamura, T., et al. 1998. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3872-3881.
30. Tsuchiya, H., Iseda, T., and Hino, O. 1996 Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res. 56:2881-2885.
31. Pal, S., Claffey, K., Cohen, H., and Mukhopadhyay, D. 1998. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J. Biol. Chem. 273:26277-26280.
32. Mukhopadhyay, D., Knebelmann, B., Cohen, H., Ananth, S., and Sukhatme, V. 1997. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17:5629-5639.